• Explore /
  • Poster
  • / Pharmacokinetic and pharmacodynamic activity evaluation of MAK683, a selective oral embryonic ectoderm development (EED) inhibitor, in adults with advanced malignancies in a first-in-human study.

Pharmacokinetic and pharmacodynamic activity evaluation of MAK683, a selective oral embryonic ectoderm development (EED) inhibitor, in adults with advanced malignancies in a first-in-human study.

Abstract Video & Slides Poster

Authors

Vincent Ribrag

Vincent Ribrag

Gustave Roussy, Villejuif, France

Vincent Ribrag , Zev A. Wainberg , Lara Iglesias Docampo , Thiruvamoor Ramkumar , Louise Barys , Shuqi Chen , Marc Raccuglia , Mélanie Wilbaux , Karen Beltz , Amy Luyt , Yu Yun Fan , Naoko Suenaga , Fangjun Luo , Xuan Dai , Clinton Lai , Jia Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

New Targets and New Technologies (non-IO)

Clinical Trial Registration Number

NCT02900651

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3083)

DOI

10.1200/JCO.2022.40.16_suppl.3083

Abstract #

3083

Poster Bd #

75

Abstract Disclosures

Similar Posters

First Author: Ben George

First Author: Gregory Lawrence Beatty

First Author: Aurelius Gabriel Omlin

First Author: Michael S. Gordon